Bendamustine-PAMAM Conjugates for Improved Apoptosis, Efficacy, and in Vivo Pharmacokinetics: A Sustainable Delivery Tactic.

Successful delivery of a chemotherapeutic agent like bendamustine still remains a challenge in clinical conditions like chronic lymphatic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma. We have conjugated bendamustine to polyamidoamine (PAMAM) dendrimers after conjugating with N-(hydroxyethyl)maleimide (spacer) via an ester bond. The particle size of PAMAM-bendamustine conjugate was 49.8 ± 2.5 nm. In vitro drug release resulted in sustained release with improved solution stability of drug up to 72 h. In a 24 h cytotoxicity study by MTT assay against human monoblastic leukemia cells (THP-1), the IC50 value for PAMAM-bendamustine was 32.1 ± 4.8 μM compared to 50.42 ± 3.4 μM and 2303 ± 106.5 μM for bendamustine and PAMAM dendrimer, respectively. Significantly higher cell uptake and apoptosis were observed in THP-1 cells by PAMAM-bendamustine conjugate which was confirmed by flow cytometry and confocal laser scanning microscopy. Preliminary in vivo studies undertaken included pharmacokinetics studies, organ distribution studies, and tumor inhibition studies. In healthy Wistar rat model (1CBM IV push model), the pharmacokinetic studies revealed that bioavailability and t1/2 increased significantly, i.e., almost 8.5-fold (193.8 ± 1.116 vs 22.8 ± 0.158 μg mL-1/h) and 5.1-fold (0.75 ± 0.005 vs 3.85 ± 0.015 h), respectively, for PAMAM-bendamustine conjugate compared to pure bendamustine ( p < 0.05), however, clearance and volume of distribution were found to be decreased compared to those of free drug. The study suggests that PAMAM-bendamustine conjugate was not only stable for the longer period but also least toxic and highly taken up by THP-1 cells to exert an anticancer effect at the reduced dose. Tumor inhibition and biodistribution studies in tumor-bearing BALB/c mice revealed that PAMAM-bendamustine conjugate was more effective than the pure drug and showed higher accumulation in the tumor.

[1]  Shashank K Singh,et al.  Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine. , 2016, International journal of biological macromolecules.

[2]  Xiaole Qi,et al.  Carboxymethyl Chitosan-Modified Polyamidoamine Dendrimer Enables Progressive Drug Targeting of Tumors via pH-Sensitive Charge Inversion. , 2016, Journal of biomedical nanotechnology.

[3]  Xinyuan Zhu,et al.  Self-Assembled Nanoparticles of Amphiphilic Twin Drug from Floxuridine and Bendamustine for Cancer Therapy. , 2015, Molecular pharmaceutics.

[4]  C. Nguyen,et al.  1H NMR Spectroscopy as an Effective Method for Predicting Molecular Weight of Polyaminoamine Dendrimers and Their Derivatives , 2015 .

[5]  J. Mes,et al.  THP-1 cell line: an in vitro cell model for immune modulation approach. , 2014, International immunopharmacology.

[6]  S. Choi,et al.  Atomic Force Microscopy Probing of Receptor–Nanoparticle Interactions for Riboflavin Receptor Targeted Gold–Dendrimer Nanocomposites , 2014, The journal of physical chemistry. B.

[7]  L. Kaminskas,et al.  Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. , 2012, Molecular pharmaceutics.

[8]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Kolesar,et al.  Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. , 2009, Clinical therapeutics.

[10]  K. Troev,et al.  HPLC study on the stability of bendamustine hydrochloride immobilized onto polyphosphoesters. , 2008, Journal of pharmaceutical and biomedical analysis.

[11]  A. Tulpule,et al.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. K. Jain,et al.  Application of dendrimer–drug complexation in the enhancement of drug solubility and bioavailability , 2008, Expert opinion on drug metabolism & toxicology.

[13]  Anil K Patri,et al.  Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. , 2005, Advanced drug delivery reviews.

[14]  T. Xu,et al.  Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. , 2005, European journal of medicinal chemistry.

[15]  Thommey P. Thomas,et al.  Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor , 2002, Pharmaceutical Research.

[16]  D. Hui,et al.  Modified Low Density Lipoprotein Enhances the Secretion of Bile Salt-stimulated Cholesterol Esterase by Human Monocyte-Macrophages , 1997, The Journal of Biological Chemistry.

[17]  L. Yang,et al.  Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. , 1996, Journal of pharmaceutical sciences.

[18]  H. Schrenk,et al.  Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[19]  L. Kass.  Esterase reactions in acute myelomonocytic leukemia. , 1977, American journal of clinical pathology.